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Purpose of review
Rathke's cleft cysts arise from embryonic remnants of 
Rathke's cleft. The purpose of this paper is to review the 
current knowledge pertaining to Rathke's cleft cysts. 
Recent studies regarding the management of Rathke's cleft 
cysts are also discussed.
Recent findings
Rathke's cleft cysts generally exhibit a benign clinical 
course. Magnetic resonance imaging is the diagnostic 
imaging study of choice. Although the most consistent sign 
to differentiate Rathke's cleft cysts is the lack of 
enhancement of the cyst wall on contrast-enhanced 
magnetic resonance images, the presence of an intracystic 
nodule of low signal intensity on T2-weighted images and 
possibly high signal intensity on T1-weighted images is 
highly characteristic of Rathke's cleft cysts. Surgical 
management is the treatment for symptomatic Rathke's 
cleft cysts, although asymptomatic lesions may be followed  
conservatively. Drainage of the cyst contents is the primary 
goal of surgery; aggressive total resection of the cyst wall, 
however, may be associated with greater endocrine 
morbidity. Recurrence may be more common than 
previously noted when a longer follow-up period is 
observed.
Summary
Incidental Rathke's cleft cysts may be followed with serial 
imaging. Symptomatic Rathke's cleft cysts are best 
removed via the transsphenoidal route. Extended 
postoperative follow-up is indicated in all patients.
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Introduction
Rathke’s cleft cysts (RCCs) are non-neoplastic cysts that 
arise from glandular rests of Rathke’s cleft in the area of 
the intermediate lobe of the pituitary gland. Commonly 
found at autopsy on a microscopic scale, 80% of RCCs 
occur at the interface between the anterior and posterior 
lobes o f the pituitary [1]. RCCs can cause visual or 
endocrine disorders when their mass compresses the 
visual apparatus, pituitary gland, or hypothalamus.
Embryology
T h e  most common theory about the origin of RCCs is 
that they develop from embryonic remnants of Rathke’s 
pouch. It is thought that during the third or fourth week 
of gestation a rostral outpouching of the ectodermal 
primitive oral cavity meets a downward projection from 
the neuroectodermal diencephalon. Together, these 
structures give rise to the anterior lobe, pars tuberalis, 
and pars intermedia of the pituitary gland [2,3]. Rathke’s 
pouch is created by the development of the adenohypo­
physis and neurohypophysis in the region of the pars 
intermedia. If  this pouch fails to regress and enlarges with 
fluid, it becomes a symptomatic RCC. Other theories 
have been proposed to explain the development of these 
lesions, including an endodermal rather than an ectoder­
mal origin [4 -6 ] or reverse metaplasia of pituitary cells 
[7,8].
Pathology
RCCs consist of a single or pseudostratified epithelium 
with an underlying layer of connective tissue. T h e  cell 
composition of the epithelium may include ciliated, 
goblet, squamous, and basal cells [6]. RCCs are classified 
pathologically as a distinct category among other cystic- 
epithelial lesions, including dermoid cysts, epidermoid 
cysts, and craniopharyngiomas.
Relationship between symptomatic Rathke’s cleft cyst 
and craniopharyngioma
RCCs often cannot be distinguished radiographically 
from craniopharyngioma and other intrasellar cysts, and 
microscopic diagnosis can be difficult. As a result, 
Harrison et al. [2] suggested that these cysts are best 
viewed as a continuum of epithelial-lined cystic lesions. 
Harrison et al. [2] detailed the histology of each of these 
intrasellar cysts separately, and also found substantial 
overlap of characteristics in their cases and in the litera­
ture; however, their descriptions o f the surgical outcomes 
were limited. We recently published [9**] a large series of 
patients with 5-year follow-up in which we suggested that
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the closer relationship between craniopharyngioma and 
RCC proposed by Harrison and colleagues [2] was sup­
ported by our recurrence results. O f the 38 patients in our 
study with a diagnosis of squamous metaplasia, 12 (32%) 
experienced a recurrence, supporting the theory that 
RCCs with squamous metaplasia represent a more 
aggressive pathological entity that may approach the 
natural history of craniopharyngioma.
Radiographic evaluation
Intrasellar cyst differential diagnosis includes epithelial 
cyst, epidermoid cyst, dermoid cyst, RCC, and craniophar­
yngioma. Magnetic resonance imaging (M RI) is the diag­
nostic study of choice in diagnosing RCCs; however, the 
signal intensity is often extremely variable on T I  and T 2- 
weighted imaging, the location of the cyst may not be 
consistent, and overall no single, unique, or consistent 
pathognomonic sign can be identified [10-12]. Further­
more, as indicated above, RCCs may appear similar to 
other cystic sellar and suprasellar lesions such as cranio­
pharyngiomas and pituitary adenomas. Various signs that 
may differentiate RCCs from other lesions include smooth 
contours, the lack of a cyst wall or extracystic solid com­
ponent, the absence of calcification, homogeneous attenu­
ation, and the absence of enhancement [1 ,10-19],
T h e  most consistent sign to differentiate RCCs from 
cystic pituitary adenomas and craniopharyngiomas that 
lack an associated solid lesion is the enhancement charac­
teristics of the cyst wall on contrast-enhanced M RI. 
RCCs do not generally enhance, whereas the other 
lesions invariably have enhancement o f their walls. 
Although RCCs can appear to have enhancement, this 
is actually caused by enhancement of the adjacent normal
pituitary gland. Dynamic pituitary studies, however, will 
clearly differentiate enhancement of the normal pituitary 
that occurs early after contrast administration from cyst 
wall enhancement that occurs after enhancement of the 
pituitary.
Another sign that can be used to confirm the diagnosis of 
RCC is the presence of an intracystic nodule, which 
may be visible in some cases of RCCs (Fig. 1) [20**]. 
T h is nodule is consistently low signal intensity on T 2 - 
weighted images, and may have high signal intensity on 
Tl-w eighted  images. A nodule has been associated with a 
pathologically confirmed RCC in 17, 43, and 11% o f cases 
described in three series in the literature [13,21,22]. In a 
recent publication. Binning et al. [20**] found that an 
intracystic nodule was demonstrated in 40% of patients 
with a tissue-confirmed diagnosis of RCC and in 47% of 
patients diagnosed radiographically. At surgery, the waxy, 
solid nodules were floating freely without a connection by 
any membrane. A pathological evaluation demonstrated 
a mucinous epithelial-lined cyst containing acellular 
proteinaceous material with a white nodule of adherent 
soft tissue that represents cellular debris. Biochemical 
studies demonstrated that the nodules consisted of 
cholesterol and protein.
Although the intracystic nodule with its characteristic 
imaging qualities is unique to RCCs, nodules may also 
occur with craniopharyngiomas. In contrast to RCCs, 
craniopharyngiomas typically have a well-defined cystic 
mass with a mural nodule, which is characteristically 
hypointense on Tl-w eighted  images and hyperintense 
on T2-weighted images, and strongly enhances hetero­
geneously with contrast [23],
Figure 1 MRI appearance of intracystic nodule in Rathke’s cleft cyst
Magnetic resonance imaging of a tissue-confirmed Rathke’s cleft cyst with a nodule in the posterior aspect of the cyst (arrow in inset) that displays high 
signal intensity on T1-weighted imaging (a) and low signal intensity on T2-weighted imaging (b). From Binning et al. [2 0 "] with permission.
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Surgical management: incidental Rathke’s 
cleft cysts
RGGs are becoming a more common incidental finding as 
neuroimaging is used more often for the evaluation of 
other conditions; however, these lesions are usually 
benign and require only conservative management. In 
their recent survey, Sanno et al. [24] found that only 
5.4% of RGGs increased in size during follow-up. Our 
experience supports the assertion that growth of these 
small, incidental RGGs may occur, but a course of 
conservative observation is warranted. We found that 
69% of patients with an incidental finding of cyst demon­
strated no growth for up to 9 years [9**]. It is our practice 
to follow all incidental presumptive RGGs with serial 
M R I studies over a 5-year period to determine the 
growth behavior of the cyst. Small lesions that do not 
change over this interval are then discontinued from 
follow-up. M RI-detected recurrence can also be followed 
with serial imaging alone if no growth progression is 
observed.
Surgical management: symptomatic Rathke’s 
cleft cysts
Surgical resection of RGGs generally improves endocrine 
and visual function [25], but aggressive resection can 
result in postoperative endocrine dysfunction. T h e  pre­
Figure 2 Endonasal transsphenoidal approach
This approach is the standard for the drainage of Rathke’s cleft cyst, and 
is usually performed through one nostril and with the aid of a microscope 
or endoscope. From Liu et al. [28] with permission.
ferred method for draining an RGG is via the transnasal- 
transsphenoidal route (Fig. 2) [26-28], with the use of an 
operative microscope or endoscope.
There exists some difference in opinion as to what the 
goals of surgery should be with respect to the aggressive­
ness of the attempted removal of the cyst wall. In 1966, 
Fager and Garter [29] advised full evacuation of the 
contents of the cyst and substantial resection of the cyst 
wall, and this has become the most common treatment 
[30,31]. Ross et al. [3] later advocated the use of cauter­
ization of the cyst wall and application of absolute alcohol 
if  the subarachnoid space was not violated, in an attempt 
to kill the cellular wall of the cyst and thus potentially 
decrease recurrence. No complications were reported in 
two series with a total of 115 patients who underwent this 
technique [3,9**]; however, blindness, anosmia, and 
partial third nerve damage were reported in a patient 
who underwent four surgeries for recurrent RGGs when 
the subarachnoid membrane was violated and the alcohol 
mixed with the cerebrospinal fluid [32].
Aggressive surgical resection of the RGG wall can result 
in postoperative endocrine dysfunction, most commonly 
diabetes insipidus. In our study [9**], 22 cases of diabetes 
insipidus developed in patients in whom it was not 
present preoperatively. In our experience, radical resec­
tion of the cyst wall was associated with higher endocrine 
morbidity: nearly half of the patients undergoing radical 
resection in our series (14/33) developed diabetes insi­
pidus postoperatively, whereas only 9% of those patients 
who underwent non-radical resection developed dia­
betes insipidus. Similarly, postoperative hypogonadism 
was more common after radical resection than after less 
radical resection (6 versus 2.5%).
Outcome
Although incidental asymptomatic lesions with imaging 
consistent with RGG can be followed conservatively, 
symptomatic RGGs are most successfully managed 
surgically. Improvements in headache, visual field defect, 
visual acuity, hyperprolactinemia, and am enorrhea- 
galactorrhea syndrome have been reported. Our data also 
show that preoperative hypopituitarism also improved 
after the removal of RGGs [9**]. This improvement 
was most impressive in growth hormone-deficient and 
hypogonadal patients, but was also observed in hypo- 
cortisolemic patients, whereas no improvement was 
seen in the eight patients with preoperative hypothyr­
oidism. Diabetes insipidus has also generally failed to 
improve.
After surgical drainage, M R I scans with 2 -3 -m m  spacing 
should be obtained in all patients at 3 months. Repeat 
M R I scans should be performed annually for 5 years, and 
approximately every 2 years thereafter.
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Recurrence
Recurrence of symptomatic RCC has been variously esti­
mated at between 0 and 33% [3,31,33-37], In a study of 53 
patients at three different institutions treated with various 
approaches [36], the authors reported an 11% recurrence 
rate. One study retrospectively reviewed 16 cases of RCC 
without recurrence, but did not include follow-up time 
[33]. Our series [9**] revealed an 18% recurrence rate in 
patients having at least a 5-year follow-up. Longer follow- 
up does seem to be associated with a greater reported 
recurrence rate, suggesting that recurrence may not be 
quite as rare as has previously been assumed.
W e found that less radical resection was not associated 
with a greater rate of recurrence, but rather that squamous 
metaplasia of the cyst wall and the use of a fat and fascial 
graft during surgery were more highly associated with 
recurrences [9**]. As a result of the high complication 
rates associated with radical resection, the improved 
endocrinological complication rates for less radical resec­
tion, and the lack of correlation between radical resection 
and a decreased recurrence rate, it appears that total 
resection of the wall may not be the optimal treatment 
for symptomatic RCCs.
Conclusion
RCCs are cystic lesions that originate embryologically as 
a remnant of the cleft in the region of the pars intermedia. 
Differentiation of RCCs from other intra and suprasellar 
cystic lesions is based on M R I characteristics, a lack of 
enhancement of the cyst wall, and the presence of 
intracystic nodules. These nodules have consistent and 
characteristic signal intensities on M RI, and are thought 
to be diagnostic of RCC when present. RCCs generally 
exhibit a benign clinical course, and incidental lesions 
may be followed conservatively. Larger symptomatic 
lesions producing endocrinopathy from pituitary compro­
mise and visual loss are handled with transsphenoidal 
drainage of the cyst, usually with histological confir­
mation of the cyst wall. In most cases, endocrinopathy 
and visual symptoms improve, but depending on the 
severity may not normalize. Postoperatively, all patients 
are monitored carefully for potential recurrence of the 
cyst over an extended (greater than 10-year) period.
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